Science 25 June 1993: Vol. 260. no. 5116, pp. 1934 - 1937 DOI: 10.1126/science.8316833

Prev | Table of Contents | Next

Articles

A Systems Perspective of Ras Signaling in Cancer.

E. C. Stites and K. S. Ravichandran (2009)
Clin. Cancer Res. 15, 1510-1513
 |  Abstract »  |  Full Text »  |  PDF »

Molecular Pathogenesis of Oral Squamous Cell Carcinoma: Implications for Therapy.

S. Choi and J.N. Myers (2008)
Journal of Dental Research 87, 14-32
 |  Abstract »  |  Full Text »  |  PDF »

Network Analysis of Oncogenic Ras Activation in Cancer.

E. C. Stites, P. C. Trampont, Z. Ma, and K. S. Ravichandran (2007)
Science 318, 463-467
 |  Abstract »  |  Full Text »  |  PDF »

Farnesyl transferase inhibitor resistance probed by target mutagenesis.

T. Raz, V. Nardi, M. Azam, J. Cortes, and G. Q. Daley (2007)
Blood 110, 2102-2109
 |  Abstract »  |  Full Text »  |  PDF »

Farnesyltransferase inhibitors inhibit T-cell cytokine production at the posttranscriptional level.

R. E. Marks, A. W. Ho, C. Robbel, T. Kuna, S. Berk, and T. F. Gajewski (2007)
Blood 110, 1982-1988
 |  Abstract »  |  Full Text »  |  PDF »

Cellular palmitoylation and trafficking of lipidated peptides.

J. M. Draper, Z. Xia, and C. D. Smith (2007)
J. Lipid Res. 48, 1873-1884
 |  Abstract »  |  Full Text »  |  PDF »

AAL881, a Novel Small Molecule Inhibitor of RAF and Vascular Endothelial Growth Factor Receptor Activities, Blocks the Growth of Malignant Glioma..

S. Sathornsumetee, A. B. Hjelmeland, S. T. Keir, R. E. McLendon, D. Batt, T. Ramsey, N. Yusuff, B.K. A. Rasheed, M. W. Kieran, A. Laforme, et al. (2006)
Cancer Res. 66, 8722-8730
 |  Abstract »  |  Full Text »  |  PDF »

Discovery and characterization of inhibitors of human palmitoyl acyltransferases..

C. E. Ducker, L. K. Griffel, R. A. Smith, S. N. Keller, Y. Zhuang, Z. Xia, J. D. Diller, and C. D. Smith (2006)
Mol. Cancer Ther. 5, 1647-1659
 |  Abstract »  |  Full Text »  |  PDF »

Thematic review series: Lipid Posttranslational Modifications. Structural biology of protein farnesyltransferase and geranylgeranyltransferase type I.

K. T. Lane and L. S. Beese (2006)
J. Lipid Res. 47, 681-699
 |  Abstract »  |  Full Text »  |  PDF »

Identification of Insulin-Like Growth Factor Binding Protein-3 as a Farnesyl Transferase Inhibitor SCH66336-Induced Negative Regulator of Angiogenesis in Head and Neck Squamous Cell Carcinoma.

S.-H. Oh, W.-Y. Kim, J.-H. Kim, M. N. Younes, A. K. El-Naggar, J. N. Myers, M. Kies, P. Cohen, F. Khuri, W. K. Hong, et al. (2006)
Clin. Cancer Res. 12, 653-661
 |  Abstract »  |  Full Text »  |  PDF »

Thematic review series: Lipid Posttranslational Modifications. Farnesyl transferase inhibitors.

A. D. Basso, P. Kirschmeier, and W. R. Bishop (2006)
J. Lipid Res. 47, 15-31
 |  Abstract »  |  Full Text »  |  PDF »

The Farnesyl Transferase Inhibitor (FTI) SCH66336 (lonafarnib) Inhibits Rheb Farnesylation and mTOR Signaling: ROLE IN FTI ENHANCEMENT OF TAXANE AND TAMOXIFEN ANTI-TUMOR ACTIVITY.

A. D. Basso, A. Mirza, G. Liu, B. J. Long, W. R. Bishop, and P. Kirschmeier (2005)
J. Biol. Chem. 280, 31101-31108
 |  Abstract »  |  Full Text »  |  PDF »

Characterization of a Human Carcinoma Cell Line Selected for Resistance to the Farnesyl Transferase Inhibitor 4-(2-(4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxamide (SCH66336).

L. M. Bruzek, J. N. Poynter, S. H. Kaufmann, and A. A. Adjei (2005)
Mol. Pharmacol. 68, 477-486
 |  Abstract »  |  Full Text »  |  PDF »

Phase I Study of the Farnesyltransferase Inhibitor BMS-214662 Given Weekly in Patients with Solid Tumors.

V. Papadimitrakopoulou, S. Agelaki, H. T. Tran, M. Kies, R. Gagel, R. Zinner, E. Kim, G. Ayers, J. Wright, and F. Khuri (2005)
Clin. Cancer Res. 11, 4151-4159
 |  Abstract »  |  Full Text »  |  PDF »

Phase I Study of BMS-214662, a Farnesyl Transferase Inhibitor in Patients With Acute Leukemias and High-Risk Myelodysplastic Syndromes.

J. Cortes, S. Faderl, E. Estey, R. Kurzrock, D. Thomas, M. Beran, G. Garcia-Manero, A. Ferrajoli, F. Giles, C. Koller, et al. (2005)
J. Clin. Oncol. 23, 2805-2812
 |  Abstract »  |  Full Text »  |  PDF »

Antitumor Activity of Orally Bioavailable Farnesyltransferase Inhibitor, ABT-100, Is Mediated by Antiproliferative, Proapoptotic, and Antiangiogenic Effects in Xenograft Models.

D. Ferguson, L. E. Rodriguez, J. P. Palma, M. Refici, K. Jarvis, J. O'Connor, G. M. Sullivan, D. Frost, K. Marsh, J. Bauch, et al. (2005)
Clin. Cancer Res. 11, 3045-3054
 |  Abstract »  |  Full Text »  |  PDF »

Phase I Pharmacokinetic and Pharmacodynamic Study of Weekly 1-Hour and 24-Hour Infusion BMS-214662, a Farnesyltransferase Inhibitor, in Patients With Advanced Solid Tumors.

J. Tabernero, F. Rojo, I. Marimon, M. Voi, J. Albanell, M. Guix, F. Vazquez, J. Carulla, M. Cooper, J. Andreu, et al. (2005)
J. Clin. Oncol. 23, 2521-2533
 |  Abstract »  |  Full Text »  |  PDF »

Protein Farnesyltransferase Inhibitor (SCH 66336) Abolishes NF-{kappa}B Activation Induced by Various Carcinogens and Inflammatory Stimuli Leading to Suppression of NF-{kappa}B-regulated Gene Expression and Up-regulation of Apoptosis.

Y. Takada, F. R. Khuri, and B. B. Aggarwal (2004)
J. Biol. Chem. 279, 26287-26299
 |  Abstract »  |  Full Text »  |  PDF »

Apoptotic and Cytostatic Farnesyltransferase Inhibitors Have Distinct Pharmacology and Efficacy Profiles in Tumor Models.

V. Manne, F. Y. F. Lee, D. K. Bol, J. Gullo-Brown, C. R. Fairchild, L. J. Lombardo, R. A. Smykla, G. D. Vite, M.-L. D. Wen, C. Yu, et al. (2004)
Cancer Res. 64, 3974-3980
 |  Abstract »  |  Full Text »  |  PDF »

p38 MAPK Activation Selectively Induces Cell Death in K-ras-mutated Human Colon Cancer Cells through Regulation of Vitamin D Receptor.

X. Qi, J. Tang, R. Pramanik, R. M. Schultz, S. Shirasawa, T. Sasazuki, J. Han, and G. Chen (2004)
J. Biol. Chem. 279, 22138-22144
 |  Abstract »  |  Full Text »  |  PDF »

Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting.

R. Kurzrock, H. M. Kantarjian, J. E. Cortes, N. Singhania, D. A. Thomas, E. F. Wilson, J. J. Wright, E. J. Freireich, M. Talpaz, and S. M. Sebti (2003)
Blood 102, 4527-4534
 |  Abstract »  |  Full Text »  |  PDF »

Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy.

J. E. Lancet and J. E. Karp (2003)
Blood 102, 3880-3889
 |  Abstract »  |  Full Text »  |  PDF »

Anti-Leukemia Effect of Perillyl Alcohol in Bcr/Abl-Transformed Cells Indirectly Inhibits Signaling through Mek in a Ras- and Raf-Independent Fashion.

S. S. Clark, L. Zhong, D. Filiault, S. Perman, Z. Ren, M. Gould, and X. Yang (2003)
Clin. Cancer Res. 9, 4494-4504
 |  Abstract »  |  Full Text »  |  PDF »

Farnesyltransferase Inhibitors: An Overview of the Results of Preclinical and Clinical Investigations.

T. B. Brunner, S. M. Hahn, A. K. Gupta, R. J. Muschel, W. G. McKenna, and E. J. Bernhard (2003)
Cancer Res. 63, 5656-5668
 |  Abstract »  |  Full Text »  |  PDF »

A Cell-Based Radioligand Binding Assay for Farnesyl: Protein Transferase Inhibitors.

R. B. Lobell, J. P. Davide, N. E. Kohl, H. D. Burns, W.-S. Eng, and R. E. Gibson (2003)
J Biomol Screen 8, 430-438
 |  Abstract »  |  PDF »

Modulation of Cellular Signaling Pathways: Prospects for Targeted Therapy in Hematological Malignancies.

F. Ravandi, M. Talpaz, and Z. Estrov (2003)
Clin. Cancer Res. 9, 535-550
 |  Abstract »  |  Full Text »  |  PDF »

Statins and stroke: evidence for cholesterol-independent effects.

P. Di Napoli, A.A. Taccardi, M. Oliver, and R. De Caterina (2002)
Eur. Heart J. 23, 1908-1921
 |  PDF »

In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway.

M. Chatterjee, D. Honemann, S. Lentzsch, K. Bommert, C. Sers, P. Herrmann, S. Mathas, B. Dorken, and R. C. Bargou (2002)
Blood 100, 3311-3318
 |  Abstract »  |  Full Text »  |  PDF »

Inhibition of Glucose- and Calcium-Induced Insulin Secretion from beta TC3 Cells by Novel Inhibitors of Protein Isoprenylation.

R. Amin, H.-Q. Chen, M. Tannous, R. Gibbs, and A. Kowluru (2002)
J. Pharmacol. Exp. Ther. 303, 82-88
 |  Abstract »  |  Full Text »  |  PDF »

Reversion of RhoC GTPase-induced Inflammatory Breast Cancer Phenotype by Treatment with a Farnesyl Transferase Inhibitor.

K. L. van Golen, L. Bao, M. M. DiVito, Z. Wu, G. C. Prendergast, and S. D. Merajver (2002)
Mol. Cancer Ther. 1, 575-583
 |  Abstract »  |  Full Text »  |  PDF »

The Ras Inhibitor S-trans,trans-Farnesylthiosalicylic Acid Chemosensitizes Human Tumor Cells Without Causing Resistance.

M. Gana-Weisz, J. Halaschek-Wiener, B. Jansen, G. Elad, R. Haklai, and Y. Kloog (2002)
Clin. Cancer Res. 8, 555-565
 |  Abstract »  |  Full Text »  |  PDF »

Farnesyltransferase Inhibitors Reverse Ras-mediated Inhibition of Fas Gene Expression.

B. Zhang, G. C. Prendergast, and R. G. Fenton (2002)
Cancer Res. 62, 450-458
 |  Abstract »  |  Full Text »  |  PDF »

Evaluation of Farnesyl:Protein Transferase and Geranylgeranyl:Protein Transferase Inhibitor Combinations in Preclinical Models.

R. B. Lobell, C. A. Omer, M. T. Abrams, H. G. Bhimnathwala, M. J. Brucker, C. A. Buser, J. P. Davide, S. J. deSolms, C. J. Dinsmore, M. S. Ellis-Hutchings, et al. (2001)
Cancer Res. 61, 8758-8768
 |  Abstract »  |  Full Text »  |  PDF »

Preclinical Antitumor Activity and Pharmacodynamic Studies with the Farnesyl Protein Transferase Inhibitor R115777 in Human Breast Cancer.

L. R. Kelland, V. Smith, M. Valenti, L. Patterson, P. A. Clarke, S. Detre, D. End, A. J. Howes, M. Dowsett, P. Workman, et al. (2001)
Clin. Cancer Res. 7, 3544-3550
 |  Abstract »  |  Full Text »  |  PDF »

Preclinical Antitumor Activity of BMS-214662, a Highly Apoptotic and Novel Farnesyltransferase Inhibitor.

W. C. Rose, F. Y. F. Lee, C. R. Fairchild, M. Lynch, T. Monticello, R. A. Kramer, and V. Manne (2001)
Cancer Res. 61, 7507-7517
 |  Abstract »  |  Full Text »  |  PDF »

Inhibition of Epidermal Growth Factor-induced RhoA Translocation and Invasion of Human Pancreatic Cancer Cells by 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase Inhibitors.

T. Kusama, M. Mukai, T. Iwasaki, M. Tatsuta, Y. Matsumoto, H. Akedo, and H. Nakamura (2001)
Cancer Res. 61, 4885-4891
 |  Abstract »  |  Full Text »  |  PDF »

Characterization of the Antitumor Effects of the Selective Farnesyl Protein Transferase Inhibitor R115777 in Vivo and in Vitro.

D. W. End, G. Smets, A. V. Todd, T. L. Applegate, C. J. Fuery, P. Angibaud, M. Venet, G. Sanz, H. Poignet, S. Skrzat, et al. (2001)
Cancer Res. 61, 131-137
 |  Abstract »  |  Full Text »

Disrupting Surfaces of Nef Required for Downregulation of CD4 and for Enhancement of Virion Infectivity Attenuates Simian Immunodeficiency Virus Replication In Vivo.

A. J. Iafrate, S. Carl, S. Bronson, C. Stahl-Hennig, T. Swigut, J. Skowronski, and F. Kirchhoff (2000)
J. Virol. 74, 9836-9844
 |  Abstract »  |  Full Text »

Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?.

C. W. M. Reuter, M. A. Morgan, and L. Bergmann (2000)
Blood 96, 1655-1669
 |  Abstract »  |  Full Text »  |  PDF »

Functional Requirement of Plant Farnesyltransferase during Development in Arabidopsis.

S. Yalovsky, A. Kulukian, M. Rodríguez-Concepción, C. A. Young, and W. Gruissem (2000)
PLANT CELL 12, 1267-1278
 |  Abstract »  |  Full Text »

Comparison of Imidazole- and 2-Methyl Imidazole-Containing Farnesyl-Protein Transferase Inhibitors: Interaction with and Metabolism by Rat Hepatic Cytochrome P450s.

C. Tang, M. Chiba, J. Nishime, J. H. Hochman, I.-W. Chen, T. M. Williams, and J. H. Lin (2000)
Drug Metab. Dispos. 28, 680-686
 |  Abstract »  |  Full Text »

The Role of Polypeptide Growth Factors in Human Carcinomas: New Targets for a Novel Pharmacological Approach.

R. E. Favoni and A. De Cupis (2000)
Pharmacol. Rev. 52, 179-206
 |  Abstract »  |  Full Text »  |  PDF »

Mouse Mammary Tumor Virus-Ki-rasB Transgenic Mice Develop Mammary Carcinomas That Can Be Growth-inhibited by a Farnesyl:Protein Transferase Inhibitor.

C. A. Omer, Z. Chen, R. E. Diehl, M. W. Conner, H. Y. Chen, M. E. Trumbauer, S. Gopal-Truter, G. Seeburger, H. Bhimnathwala, M. T. Abrams, et al. (2000)
Cancer Res. 60, 2680-2688
 |  Abstract »  |  Full Text »

Inhibition of N-methyl-N-nitrosourea- and 7,12-dimethylbenz[a] anthracene-induced rat mammary tumorigenesis by dietary cholesterol is independent of Ha-ras mutations.

A. El-Sohemy and M. C. Archer (2000)
Carcinogenesis 21, 827-831
 |  Abstract »  |  Full Text »  |  PDF »

Phase I and Pharmacokinetic Study of Farnesyl Protein Transferase Inhibitor R115777 in Advanced Cancer.

J. Zujewski, I. D. Horak, C. J. Bol, R. Woestenborghs, C. Bowden, D. W. End, V. K. Piotrovsky, J. Chiao, R. T. Belly, A. Todd, et al. (2000)
J. Clin. Oncol. 18, 927
 |  Abstract »  |  Full Text »  |  PDF »

Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyltransferase inhibitors.

P. D. Emanuel, R. C. Snyder, T. Wiley, B. Gopurala, and R. P. Castleberry (2000)
Blood 95, 639-645
 |  Abstract »  |  Full Text »  |  PDF »

Effect of farnesyltransferase inhibitor FTI-276 on established lung adenomas from A/J mice induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.

L. E. Lantry, Z. Zhang, R. Yao, K. A. Crist, Y. Wang, J. Ohkanda, A. D. Hamilton, S. M. Sebti, R. A. Lubet, and M. You (2000)
Carcinogenesis 21, 113-116
 |  Abstract »  |  Full Text »  |  PDF »

Ras Protein Farnesyltransferase: A Strategic Target for Anticancer Therapeutic Development.

E. K. Rowinsky, J. J. Windle, and D. D. Von Hoff (1999)
J. Clin. Oncol. 17, 3631-3652
 |  Abstract »  |  Full Text »  |  PDF »

Geranylgeranylated RhoB Mediates Suppression of Human Tumor Cell Growth by Farnesyltransferase Inhibitors.

W. Du and G. C. Prendergast (1999)
Cancer Res. 59, 5492-5496
 |  Abstract »  |  Full Text »  |  PDF »

A Mutant Form of Human Protein Farnesyltransferase Exhibits Increased Resistance to Farnesyltransferase Inhibitors.

K. Del Villar, J. Urano, L. Guo, and F. Tamanoi (1999)
J. Biol. Chem. 274, 27010-27017
 |  Abstract »  |  Full Text »  |  PDF »

Activation of the PI3'K-AKT Pathway Masks the Proapoptotic Effects of Farnesyltransferase Inhibitors.

W. Du, A. Liu, and G. C. Prendergast (1999)
Cancer Res. 59, 4208-4212
 |  Abstract »  |  Full Text »  |  PDF »

Chemoprevention by curcumin during the promotion stage of tumorigenesis of mammary gland in rats irradiated with {gamma}-rays.

H. Inano, M. Onoda, N. Inafuku, M. Kubota, Y. Kamada, T. Osawa, H. Kobayashi, and K. Wakabayashi (1999)
Carcinogenesis 20, 1011-1018
 |  Abstract »  |  Full Text »  |  PDF »

Elevation of {{alpha}}2(I) Collagen, a Suppressor of Ras Transformation, Is Required for Stable Phenotypic Reversion by Farnesyltransferase Inhibitors.

W. Du, P. F. Lebowitz, and G. C. Prendergast (1999)
Cancer Res. 59, 2059-2063
 |  Abstract »  |  Full Text »  |  PDF »

High-level expression, purification, kinetic characterization and crystallization of protein farnesyltransferase ß-subunit C-terminal mutants.

Z. Wu, M. Demma, C. L. Strickland, R. Syto, H. V. Le, W. T. Windsor, and P. C. Weber (1999)
Protein Eng. Des. Sel. 12, 341-348
 |  Abstract »  |  Full Text »  |  PDF »

RAS and Leukemia: From Basic Mechanisms to Gene-Directed Therapy.

D. M. Beaupre and R. Kurzrock (1999)
J. Clin. Oncol. 17, 1071
 |  Abstract »  |  Full Text »  |  PDF »

Cell Growth Inhibition by Farnesyltransferase Inhibitors Is Mediated by Gain of Geranylgeranylated RhoB.

W. Du, P. F. Lebowitz, and G. C. Prendergast (1999)
Mol. Cell. Biol. 19, 1831-1840
 |  Abstract »  |  Full Text »  |  PDF »

Treatment with Farnesyl-Protein Transferase Inhibitor Induces Regression of Mammary Tumors in Transforming Growth Factor (TGF) {{alpha}} and TGF{{alpha}}/neu Transgenic Mice by Inhibition of Mitogenic Activity and Induction of Apoptosis.

P. Norgaard, B. Law, H. Joseph, D. L. Page, Y. Shyr, D. Mays, J. A. Pietenpol, N. E. Kohl, A. Oliff, R. J. Coffey Jr., et al. (1999)
Clin. Cancer Res. 5, 35-42
 |  Abstract »  |  Full Text »  |  PDF »

Protein Farnesyltransferase from Trypanosoma brucei. A HETERODIMER OF 61- AND 65-kDa SUBUNITS AS A NEW TARGET FOR ANTIPARASITE THERAPEUTICS.

K. Yokoyama, P. Trobridge, F. S. Buckner, W. C. Van Voorhis, K. D. Stuart, and M. H. Gelb (1998)
J. Biol. Chem. 273, 26497-26505
 |  Abstract »  |  Full Text »  |  PDF »

Involvement of Ras/MAP Kinase in the Regulation of Ca2+ Channels in Adult Bullfrog Sympathetic Neurons by Nerve Growth Factor.

S. Lei, W. F. Dryden, and P. A. Smith (1998)
J Neurophysiol 80, 1352-1361
 |  Abstract »  |  Full Text »  |  PDF »

Farnesyltransferase inhibitors induce dramatic morphological changes of KNRK cells that are blocked by microtubule interfering agents.

N. Suzuki, K. Del Villar, and F. Tamanoi (1998)
PNAS 95, 10499-10504
 |  Abstract »  |  Full Text »  |  PDF »

Inhibiting geranylgeranylation blocks growth and promotes apoptosis in pulmonary vascular smooth muscle cells.

W. W. Stark Jr., M. A. Blaskovich, B. A. Johnson, Y. Qian, A. Vasudevan, B. Pitt, A. D. Hamilton, S. M. Sebti, and P. Davies (1998)
Am J Physiol Lung Cell Mol Physiol 275, L55-L63
 |  Abstract »  |  Full Text »  |  PDF »

Impact of oncogenes in tumor angiogenesis: Mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells.

F. Okada, J. W. Rak, B. St. Croix, B. Lieubeau, M. Kaya, L. Roncari, S. Shirasawa, T. Sasazuki, and R. S. Kerbel (1998)
PNAS 95, 3609-3614
 |  Abstract »  |  Full Text »  |  PDF »

Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones.

M. M. Moasser, L. Sepp-Lorenzino, N. E. Kohl, A. Oliff, A. Balog, D.-S. Su, S. J. Danishefsky, and N. Rosen (1998)
PNAS 95, 1369-1374
 |  Abstract »  |  Full Text »  |  PDF »

A Farnesyltransferase Inhibitor Induces Tumor Regression in Transgenic Mice Harboring Multiple Oncogenic Mutations by Mediating Alterations in Both Cell Cycle Control and Apoptosis.

R. E. Barrington, M. A. Subler, E. Rands, C. A. Omer, P. J. Miller, J. E. Hundley, S. K. Koester, D. A. Troyer, D. J. Bearss, M. W. Conner, et al. (1998)
Mol. Cell. Biol. 18, 85-92
 |  Abstract »  |  Full Text »

Inhibition of 3-Hydroxy-3-methylglutaryl (HMG)-CoA Reductase Blocks Hypoxia-mediated Down-regulation of Endothelial Nitric Oxide Synthase.

U. Laufs, V. L. Fata, and J. K. Liao (1997)
J. Biol. Chem. 272, 31725-31729
 |  Abstract »  |  Full Text »  |  PDF »

Mutational Analysis of Conserved Residues of the beta -Subunit of Human Farnesyl:Protein Transferase.

A. M. Kral, R. E. Diehl, S. J. deSolms, T. M. Williams, N. E. Kohl, and C. A. Omer (1997)
J. Biol. Chem. 272, 27319-27323
 |  Abstract »  |  Full Text »  |  PDF »

Substrate specificity determinants in the farnesyltransferase beta -subunit.

C. E. Trueblood, V. L. Boyartchuk, and J. Rine (1997)
PNAS 94, 10774-10779
 |  Abstract »  |  Full Text »  |  PDF »

Juvenile Myelomonocytic Leukemia.

M. Arico, A. Biondi, and C.-H. Pui (1997)
Blood 90, 479-488
 |  Full Text »  |  PDF »

Direct Demonstration of Geranylgeranylation and Farnesylation of Ki-Ras in Vivo.

C. A. Rowell, J. J. Kowalczyk, M. D. Lewis, and A. M. Garcia (1997)
J. Biol. Chem. 272, 14093-14097
 |  Abstract »  |  Full Text »  |  PDF »

K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors.

D. B. Whyte, P. Kirschmeier, T. N. Hockenberry, I. Nunez-Oliva, L. James, J. J. Catino, W. R. Bishop, and J.-K. Pai (1997)
J. Biol. Chem. 272, 14459-14464
 |  Abstract »  |  Full Text »  |  PDF »

Inhibition of Protein Geranylgeranylation Causes a Superinduction of Nitric-oxide Synthase-2 by Interleukin-1beta in Vascular Smooth Muscle Cells.

J. D. Finder, J. L. Litz, M. A. Blaskovich, T. F. McGuire, Y. Qian, A. D. Hamilton, P. Davies, and S. M. Sebti (1997)
J. Biol. Chem. 272, 13484-13488
 |  Abstract »  |  Full Text »  |  PDF »

Substrate Binding Is Required for Release of Product from Mammalian Protein Farnesyltransferase.

W. R. Tschantz, E. S. Furfine, and P. J. Casey (1997)
J. Biol. Chem. 272, 9989-9993
 |  Abstract »  |  Full Text »  |  PDF »

Characterization of Ha-Ras, N-Ras, Ki-Ras4A, and Ki-Ras4B as in Vitro Substrates for Farnesyl Protein Transferase and Geranylgeranyl Protein Transferase Type I.

F. L. Zhang, P. Kirschmeier, D. Carr, L. James, R. W. Bond, L. Wang, R. Patton, W. T. Windsor, R. Syto, R. Zhang, et al. (1997)
J. Biol. Chem. 272, 10232-10239
 |  Abstract »  |  Full Text »  |  PDF »

Amino Acid Substitutions That Convert the Protein Substrate Specificity of Farnesyltransferase to That of Geranylgeranyltransferase Type I.

K. Del Villar, H. Mitsuzawa, W. Yang, I. Sattler, and F. Tamanoi (1997)
J. Biol. Chem. 272, 680-687
 |  Abstract »  |  Full Text »  |  PDF »

Selection of Potent Inhibitors of Farnesyl-protein Transferase from a Synthetic Tetrapeptide Combinatorial Library.

A. Wallace, K. S. Koblan, K. Hamilton, D. J. Marquis-Omer, P. J. Miller, S. D. Mosser, C. A. Omer, M. D. Schaber, R. Cortese, A. Oliff, et al. (1996)
J. Biol. Chem. 271, 31306-31311
 |  Abstract »  |  Full Text »  |  PDF »

Effect of Insulin on Farnesyltransferase Activity in 3T3-L1 Adipocytes.

M. L. Goalstone and B. Draznin (1996)
J. Biol. Chem. 271, 27585-27589
 |  Abstract »  |  Full Text »  |  PDF »

Rin, a Neuron-Specific and Calmodulin-Binding Small G-Protein, and Rit Define a Novel Subfamily of Ras Proteins.

C.-H. J. Lee, N. G. Della, C. E. Chew, and D. J. Zack (1996)
J. Neurosci. 16, 6784-6794
 |  Abstract »  |  Full Text »  |  PDF »

Dose Intensity of Chemotherapy for Childhood Cancers.

M. Smith, J. Abrams, E. L. Trimble, and R. S. Ungerleider (1996)
Oncologist 1, 293-304
 |  Abstract »  |  Full Text »  |  PDF »

Stimulation of Mouse Osteopontin Promoter by v-Src Is Mediated by a CCAAT Box-binding Factor.

K.-i. Tezuka, D. T. Denhardt, G. A. Rodan, and S.-i. Harada (1996)
J. Biol. Chem. 271, 22713-22717
 |  Abstract »  |  Full Text »  |  PDF »

Differential Activation of Mitogen-activated Protein Kinases by Nitric Oxide-related Species.

H. M. Lander, A. T. Jacovina, R. J. Davis, and J. M. Tauras (1996)
J. Biol. Chem. 271, 19705-19709
 |  Abstract »  |  Full Text »  |  PDF »

Disruption of Oncogenic K-Ras4B Processing and Signaling by a Potent Geranylgeranyltransferase I Inhibitor.

E. C. Lerner, Y. Qian, A. D. Hamilton, and S.ïd M. Sebti (1995)
J. Biol. Chem. 270, 26770-26773
 |  Abstract »  |  Full Text »  |  PDF »

Ras CAAX Peptidomimetic FTI-277 Selectively Blocks Oncogenic Ras Signaling by Inducing Cytoplasmic Accumulation of Inactive Ras-Raf Complexes.

E. C. Lerner, Y. Qian, M. A. Blaskovich, R. D. Fossum, A. Vogt, J. Sun, A. D. Cox, C. J. Der, A. D. Hamilton, and S.ïd M. Sebti (1995)
J. Biol. Chem. 270, 26802-26806
 |  Abstract »  |  Full Text »  |  PDF »

Selective Inhibition of Ras-dependent Cell Growth by Farnesylthiosalisylic Acid.

M. Marom, R. Haklai, G. Ben-Baruch, D. Marciano, Y. Egozi, and Y. Kloog (1995)
J. Biol. Chem. 270, 22263-22270
 |  Abstract »  |  Full Text »  |  PDF »

Differential Effects of Monoterpenes and Lovastatin on RAS Processing.

R. J. Hohl and K. Lewis (1995)
J. Biol. Chem. 270, 17508-17512
 |  Abstract »  |  Full Text »  |  PDF »

Tyrosine kinase inhibition: an approach to drug development.

A Levitzki and A Gazit (1995)
Science 267, 1782-1788
 |  Abstract »  |  PDF »

A Non-peptide Mimetic of Ras-CAAX: Selective Inhibition of Farnesyltransferase and Ras Processing.

A. Vogt, Y. Qian, M. A. Blaskovich, R. D. Fossum, A. D. Hamilton, and S. M. Sebti (1995)
J. Biol. Chem. 270, 660-664
 |  Abstract »  |  Full Text »  |  PDF »

Oncology and Hematology.

J. E. Karp and S. Broder (1994)
JAMA 271, 1693-1695
 |  Abstract »  |  PDF »

Expression of prelamin A but not mature lamin A confers sensitivity of DNA biosynthesis to lovastatin on F9 teratocarcinoma cells.

M Sinensky, T McLain, and K Fantle (1994)
J. Cell Sci. 107, 2215-2218
 |  Abstract »  |  PDF »

Prenylation-dependent Association of Protein-tyrosine Phosphatases PRL-1, -2, and -3 with the Plasma Membrane and the Early Endosome.

Q. Zeng, X. Si, H. Horstmann, Y. Xu, W. Hong, and C. J. Pallen (2000)
J. Biol. Chem. 275, 21444-21452
 |  Abstract »  |  Full Text »  |  PDF »

Single Cell Ras-GTP Analysis Reveals Altered Ras Activity in a Subpopulation of Neurofibroma Schwann Cells but Not Fibroblasts.

L. S. Sherman, R. Atit, T. Rosenbaum, A. D. Cox, and N. Ratner (2000)
J. Biol. Chem. 275, 30740-30745
 |  Abstract »  |  Full Text »  |  PDF »

Identification of a Novel Ligand-Receptor Pair Constitutively Activated by ras Oncogenes.

R. Zhang, Z. Tan, and P. Liang (2000)
J. Biol. Chem. 275, 24436-24443
 |  Abstract »  |  Full Text »  |  PDF »

Farnesyl Transferase Inhibitors Block the Farnesylation of CENP-E and CENP-F and Alter the Association of CENP-E with the Microtubules.

H. R. Ashar, L. James, K. Gray, D. Carr, S. Black, L. Armstrong, W. R. Bishop, and P. Kirschmeier (2000)
J. Biol. Chem. 275, 30451-30457
 |  Abstract »  |  Full Text »  |  PDF »

Interaction of Farnesylated PRL-2, a Protein-tyrosine Phosphatase, with the beta -Subunit of Geranylgeranyltransferase II.

X. Si, Q. Zeng, C. H. Ng, W. Hong, and C. J. Pallen (2001)
J. Biol. Chem. 276, 32875-32882
 |  Abstract »  |  Full Text »  |  PDF »

The crystal structure of human protein farnesyltransferase reveals the basis for inhibition by CaaX tetrapeptides and their mimetics.

S. B. Long, P. J. Hancock, A. M. Kral, H. W. Hellinga, and L. S. Beese (2001)
PNAS 98, 12948-12953
 |  Abstract »  |  Full Text »  |  PDF »

To Advertise   |   Find Products